Cancer immunoediting by the innate immune system in the absence of adaptive immunity

Journal of Experimental Medicine

Volumn 209, Issue 10, 2012, Pages 1869-1882

  O'Sullivan, Timothy ^a   Saddawi Konefka, Robert ^a   Koebel, William Vermi ^b,c   Arthur, Cora ^c   White, J Michael ^c   Uppaluri, Ravi ^c   Andrews, Daniel M ^d,e   Ngiow, Shin Foong ^d,e   Teng, Michele W L ^d,e   Smyth, Mark J ^d,e   Schreiber, Robert D ^c   Bui, Jack D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; CD40 ANTIGEN; GAMMA INTERFERON; RAG2 PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER IMMUNOEDITING; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; INNATE IMMUNITY; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RNA EDITING; SARCOMA CELL; WILD TYPE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, CD40; CELL LINE, TUMOR; DNA-BINDING PROTEINS; GENETIC PREDISPOSITION TO DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNITY, INNATE; IMMUNOMODULATION; INTERFERON-GAMMA; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; KILLER CELLS, NATURAL; MACROPHAGES; MICE; MICE, KNOCKOUT; NEOPLASMS; PHENOTYPE; SARCOMA; TRANSPLANTATION, ISOGENEIC;

EID: 84870288924     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20112738     Document Type: Article

References (57)

1. Balkwill, F., and L.M. Coussens. 2004. Cancer: an inflammatory link. Nature. 431:405-406. http://dx.doi.org/10.1038/431405a
2. Beatty, G.L., E.G. Chiorean, M.P. Fishman, B. Saboury, U.R. Teitelbaum, W. Sun, R.D. Huhn, W. Song, D. Li, L.L. Sharp, et al. 2011. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 331:1612-1616. http://dx.doi.org/ 10.1126/science.1198443
3. Ben-Neriah, Y., and M. Karin. 2011. Inflammation meets cancer, with NF-kB as the matchmaker. Nat. Immunol. 12:715-723. http://dx.doi.org/10.1038/ni.2060
4. Boon, T., and O. Kellermann. 1977. Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc. Natl. Acad. Sci. USA. 74:272-275. http://dx.doi.org/10.1073/pnas.74.1.272
5. Buhtoiarov, I.N., H. Lum, G. Berke, D.M. Paulnock, P.M. Sondel, and A.L. Rakhmilevich. 2005. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J. Immunol. 174:6013-6022.
6. Bui, J.D., L.N. Carayannopoulos, L.L. Lanier, W.M. Yokoyama, and R.D. Schreiber. 2006. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J. Immunol. 176:905-913.
7. Cao, X., E.W. Shores, J. Hu-Li, M.R. Anver, B.L. Kelsall, S.M. Russell, J. Drago, M. Noguchi, A. Grinberg, E.T. Bloom, et al. 1995. Defective lymphoid development in mice lacking expression of the common cytokine receptor γ chain. Immunity. 2:223-238. http://dx.doi.org/10.1016/ 1074-7613(95)90047-0
8. Chao, M.P., S. Jaiswal, R. Weissman-Tsukamoto, A.A. Alizadeh, A.J. Gentles, J. Volkmer, K. Weiskopf, S.B. Willingham, T. Raveh,C.Y. Park, R. Majeti, and I.L. Weissman. 2010. Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47. Science Translational Medicine. 2:63ra94.
9. Cretney, E., K. Takeda, H. Yagita, M. Glaccum, J.J. Peschon, and M.J. Smyth. 2002. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168:1356-1361.
10. Crowe, N.Y., M.J. Smyth, and D.I. Godfrey. 2002. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196:119-127. http://dx.doi.org/10.1084/jem.20020092
11. Dunn, G.P., L.J. Old, and R.D. Schreiber. 2004a. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 21:137-148. http://dx.doi.org/10.1016/j.immuni.2004.07.017
12. Dunn, G.P., L.J. Old, and R.D. Schreiber. 2004b. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22:329-360. http://dx.doi.org/10.1146/annurev.immunol.22.012703.104803
13. Dunn, G.P., A.T. Bruce, K.C.F. Sheehan, V. Shankaran, R. Uppaluri, J.D. Bui, M.S. Diamond, C.M. Koebel, C. Arthur, J.M. White, and R.D. Schreiber. 2005. A critical function for type I interferons in cancer immunoediting. Nat. Immunol. 6:722-729. http://dx.doi.org/10.1038/ ni1213
14. Flood, P.M., H. Schreiber, and Y. Ron. 1987. Protective immunity to progressive tumors can be induced by antigen presented on regressor tumors. J. Immunol. 138:3573-3579.
15. Gazit, R., R. Gruda, M. Elboim, T.I. Arnon, G. Katz, H. Achdout, J. Hanna, U. Qimron, G. Landau, E. Greenbaum, et al. 2006. Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat. Immunol. 7:517-523. http://dx.doi.org/10.1038/ni1322
16. Ghassabeh, G.H., P. De Baetselier, L. Brys, W. Noël, J.A. Van Ginderachter, S. Meerschaut, A. Beschin, F. Brombacher, and G. Raes. 2006. Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo in different pathologic conditions. Blood. 108:575-583. http://dx.doi.org/10.1182/blood-2005-04-1485
17. Gilfillan, S., C.J. Chan, M. Cella, N.M. Haynes, A.S. Rapaport, K.S. Boles, D.M. Andrews, M.J. Smyth, and M. Colonna. 2008. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J. Exp. Med. 205:2965-2973. http://dx.doi.org/10.1084/jem.20081752
18. Gordon, S., and P.R. Taylor. 2005. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5:953-964. http://dx.doi.org/10.1038/nri1733
19. Guerra, N., Y.X. Tan, N.T. Joncker, A. Choy, F. Gallardo, N. Xiong, S. Knoblaugh, D. Cado, N.M. Greenberg, and D.H. Raulet. 2008. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity. 28:571-580. http://dx.doi.org/10.1016/j.immuni.2008.02.016
20. Hanahan, D., and R.A. Weinberg. 2011. Hallmarks of cancer: the next generation. Cell. 144:646-674. http://dx.doi.org/10.1016/j.cell.2011.02.013
21. Hibbs, J.B. Jr., L.H. Lambert Jr., and J.S. Remington. 1971. Resistance to murine tumors conferred by chronic infection with intracellular protozoa, Toxoplasma gondii and Besnoitia jellisoni. J. Infect. Dis. 124:587-592. http://dx.doi.org/10.1093/infdis/124.6.587
22. Hibbs, J.B. Jr., L.H. Lambert Jr., and J.S. Remington. 1972. Control of carcinogenesis: a possible role for the activated macrophage. Science. 177:998-1000. http://dx.doi.org/10.1126/science.177.4053.998
23. Iguchi-Manaka, A., H. Kai, Y. Yamashita, K. Shibata, S. Tahara-Hanaoka, S.I. Honda, T. Yasui, H. Kikutani, K. Shibuya, and A. Shibuya. 2008. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J. Exp. Med. 205:2959-2964. http://dx.doi.org/10.1084/jem.20081611
24. Jaiswal, S., C.H.M. Jamieson, W.W. Pang, C.Y. Park, M.P. Chao, R. Majeti, D. Traver, N. van Rooijen, and I.L. Weissman. 2009. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 138:271-285. http://dx.doi.org/10.1016/j.cell.2009.05.046
25. Kleinerman, E.S., K.L. Erickson, A.J. Schroit, W.E. Fogler, and I.J. Fidler. 1983. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res. 43:2010-2014.
26. Koebel, C.M., W. Vermi, J.B. Swann, N. Zerafa, S.J. Rodig, L.J. Old, M.J. Smyth, and R.D. Schreiber. 2007. Adaptive immunity maintainsoccult cancer in an equilibrium state. Nature. 450:903-907. http://dx.doi.org/10.1038/nature06309
27. Kripke, M.L. 1974. Antigenicity of murine skin tumors induced by ultraviolet light. J. Natl. Cancer Inst. 53:1333-1336.
28. Lewis, C.E., and J.W. Pollard. 2006. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66:605-612. http://dx.doi.org/10.1158/0008-5472.CAN-05-4005
29. Lum, H.D., I.N. Buhtoiarov, B.E. Schmidt, G. Berke, D.M. Paulnock, P.M. Sondel, and A.L. Rakhmilevich. 2006. Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha. Immunology. 118:261-270. http://dx.doi.org/10.1111/ j.1365-2567.2006.02366.x
30. Majeti, R., M.P. Chao, A.A. Alizadeh, W.W. Pang, S. Jaiswal, K.D. Gibbs Jr., N. van Rooijen, and I.L. Weissman. 2009. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 138:286-299. http://dx.doi.org/10.1016/j.cell.2009.05.045
31. Martinez, F.O., L. Helming, and S. Gordon. 2009. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27:451-483. http://dx.doi.org/10.1146/annurev.immunol.021908.132532
32. Movahedi, K., D. Laoui, C. Gysemans, M. Baeten, G. Stangé, J. Van den Bossche, M. Mack, D. Pipeleers, P. In't Veld, P. De Baetselier, and J.A. Van Ginderachter. 2010. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 70:5728-5739. http://dx.doi.org/10.1158/0008-5472.CAN-09-4672
33. O'Sullivan, T., G.P. Dunn, D.Y. Lacoursiere, R.D. Schreiber, and J.D. Bui. 2011. Cancer immunoediting of the NK group 2D ligand H60a. J. Immunol. 187:3538-3545. http://dx.doi.org/10.4049/jimmunol.1100413
34. Pace, J.L., S.W. Russell, R.D. Schreiber, A. Altman, and D.H. Katz. 1983. Macrophage activation: priming activity from a T-cell hybridoma is attributable to interferon-gamma. Proc. Natl. Acad. Sci. USA. 80:3782-3786. http://dx.doi.org/10.1073/pnas.80.12.3782
35. Rakhmilevich, A.L., I.N. Buhtoiarov, M. Malkovsky, and P.M. Sondel. 2008. CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors. Cancer Immunology. Immunotherapeutics. 57:1151-1160. http://dx.doi.org/10.1007/s00262-007-0447-4
36. Raulet, D.H., and N. Guerra. 2009. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat. Rev. Immunol. 9:568-580. http://dx.doi.org/10.1038/nri2604
37. Schreiber, R.D., J.L. Pace, S.W. Russell, A. Altman, and D.H. Katz. 1983. Macrophage-activating factor produced by a T cell hybridoma: physiochemical and biosynthetic resemblance to gamma-interferon. J. Immunol. 131:826-832.
38. Schreiber, R.D., L.J. Old, and M.J. Smyth. 2011. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 331:1565-1570. http://dx.doi.org/10.1126/science.1203486
39. Shankaran, V., H. Ikeda, A.T. Bruce, J.M. White, P.E. Swanson, L.J. Old, and R.D. Schreiber. 2001. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 410:1107-1111. http://dx.doi.org/10.1038/35074122
40. Shinkai, Y., G. Rathbun, K.P. Lam, E.M. Oltz, V. Stewart, M. Mendelsohn, J. Charron, M. Datta, F. Young, A.M. Stall, et al. 1992. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 68:855-867. http://dx.doi.org/ 10.1016/0092-8674(92)90029-C
41. Sica, A., P. Larghi, A. Mancino, L. Rubino, C. Porta, M.G. Totaro, M. Rimoldi, S.K. Biswas, P. Allavena, and A. Mantovani. 2008. Macrophage polarization in tumour progression. Semin. Cancer Biol. 18:349-355. http://dx.doi.org/10.1016/j.semcancer.2008.03.004
42. Smyth, M.J., K.Y. Thia, S.E. Street, E. Cretney, J.A. Trapani, M. Taniguchi, T. Kawano, S.B. Pelikan, N.Y. Crowe, and D.I. Godfrey. 2000. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191:661-668. http://dx.doi.org/10.1084/jem.191.4.661
43. Smyth, M.J., N.Y. Crowe, and D.I. Godfrey. 2001. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. 13:459-463. http://dx.doi.org/10.1093/ intimm/13.4.459
44. Smyth, M.J., Y. Hayakawa, K. Takeda, and H. Yagita. 2002. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer. 2:850-861. http://dx.doi.org/10.1038/nrc928
45. Smyth, M.J., J. Swann, E. Cretney, N. Zerafa, W.M. Yokoyama, and Y. Hayakawa. 2005. NKG2D function protects the host from tumor initiation. J. Exp. Med. 202:583-588. http://dx.doi.org/10.1084/jem.20050994
46. Smyth, M.J., G.P. Dunn, and R.D. Schreiber. 2006. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 90:1-50. http://dx.doi.org/10.1016/S0065-2776(06)90001-7
47. Street, S.E.A., E. Cretney, and M.J. Smyth. 2001. Perforin and interferongamma activities independently control tumor initiation, growth, and metastasis. Blood. 97:192-197. http://dx.doi.org/10.1182/blood.V97.1.192
48. Street, S.E.A., Y. Hayakawa, Y. Zhan, A.M. Lew, D. MacGregor, A.M. Jamieson, A. Diefenbach, H. Yagita, D.I. Godfrey, and M.J. Smyth. 2004. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J. Exp. Med. 199:879-884. http://dx.doi.org/10.1084/jem.20031981
49. Takahashi, K., and S. Yamanaka. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 126:663-676. http://dx.doi.org/10.1016/j.cell.2006.07.024
50. Takeda, K., M.J. Smyth, E. Cretney, Y. Hayakawa, N. Kayagaki, H. Yagita, and K. Okumura. 2002. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195:161-169. http://dx.doi.org/10.1084/ jem.20011171
51. Van den Broek, M.E., D. Kägi, F. Ossendorp, R. Toes, S. Vamvakas, W.K. Lutz, C.J. Melief, R.M. Zinkernagel, and H. Hengartner. 1996. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184:1781-1790. http://dx.doi.org/10.1084/jem.184.5.1781
52. Van Ginderachter, J.A., S. Meerschaut, Y. Liu, L. Brys, K. De Groeve, G. Hassanzadeh Ghassabeh, G. Raes, and P. De Baetselier. 2006. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood. 108:525-535. http://dx.doi.org/10.1182/blood-2005-09-3777
53. Vesely, M.D., M.H. Kershaw, R.D. Schreiber, and M.J. Smyth. 2011. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29:235-271. http://dx.doi.org/10.1146/annurev-immunol-031210-101324
54. Wang, S.-C., J.-H. Hong, C. Hsueh, and C.-S. Chiang. 2012. Tumorsecreted SDF-1 promotes glioma invasiveness and TAM tropism toward hypoxia in a murine astrocytoma model. Lab. Invest. 92:151-162. http:// dx.doi.org/10.1038/labinvest.2011.128
55. Weinberg, J.B., H.A. Chapman Jr., and J.B. Hibbs Jr. 1978. Characterization of the effects of endotoxin on macrophage tumor cell killing. J. Immunol. 121:72-80.
56. Yokoyama, W.M., and B.F.M. Plougastel. 2003. Immune functions encoded by the natural killer gene complex. Nat. Rev. Immunol. 3:304-316. http://dx.doi.org/10.1038/nri1055
57. Zitvogel, L., O. Kepp, L. Senovilla, L. Menger, N. Chaput, and G. Kroemer. 2010. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin. Cancer Res. 16:3100-3104. http://dx.doi.org/10.1158/1078-0432.CCR-09-2891